Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.

Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.

Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.

《心血管药物与治疗》旨在客观地报道心血管药物、设备和细胞疗法从实验室到临床的开发过程，以及时且有用的形式为您提供最需要的信息，它以全新且充满活力的视角看待这一动态领域的进展。

《心血管药物与治疗》关注最令人兴奋的新型治疗药物研究，重点关注动脉粥样硬化、高脂血症、糖尿病、缺血综合征和心律失常的发展。该期刊是当前和相关信息的权威来源，对于寻求新颖、突破性研究的基础和临床研究人员以及寻求为患者提供最佳服务的心脏病专家来说，这些信息都是必不可少的。

《心血管药物与治疗》为您提供一个简明扼要的参考工具，被公认为世界上最好的参考工具之一，被收录在 Web of Science 和 PubMed/Medline 等文摘和索引服务中。定期的文章和频繁的专题专题为您提供了最新的信息来源，这些信息是针对不断发展的领域对准确信息的需求而定义的。《心血管药物和治疗》是一本细致而准确的指南，带您穿越新产品和疗法的迷宫，为您提供有关心血管药理学的详细信息，您将一次又一次地参考这些信息。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映医学-心血管系统领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为3.1，平均审稿速度为 约4.5月 ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。